Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age.

@article{Bradley2014SingledosePO,
  title={Single-dose pharmacokinetics of daptomycin in pediatric patients 3-24 months of age.},
  author={J. Stuart Bradley and David P Benziger and Paula Bokesch and Richard Jacobs},
  journal={The Pediatric infectious disease journal},
  year={2014},
  volume={33 9},
  pages={936-9}
}
BACKGROUND Daptomycin is approved for treatment of complicated skin/skin structure infections and Staphylococcus aureus bloodstream infections (bacteremia) in adults. This study was undertaken to determine the pharmacokinetics of daptomycin in pediatric patients 3-24 months of age with proven/suspected bacterial infection. METHODS In this phase 1, multicenter, open-label, noncomparative pharmacokinetic and safety study, patients were enrolled in 3 age groups: 3-6, 7-12 and 13-24 months… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
2 Extracted Citations
0 Extracted References
Similar Papers

Similar Papers

Loading similar papers…